PCR Controls
Summary sheet of NAT, nucleic acid NAT controls
(I) Certified reference materials
Number |
Name |
Approval Number |
Standard Value |
Dimensions |
GBDS-BW-001 |
Human cytomegalovirus DNA (HCMV DNA) liquid reference material |
GBW(E)090676 |
(1.8±0.7)E+03 IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-BW-002 |
GBW(E)090677 |
(2.0±0.7)E+04 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-003 |
GBW(E)090678 |
(2.4±0.7)E+05 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-004 |
EB virus DNA (EBV DNA) liquid reference material |
GBW(E)090679 |
(5.0±1.8)E+03 IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-BW-005 |
GBW(E)090680 |
(5.1±1.1)E+04 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-006 |
GBW(E)090681 |
(5.4±1.0)E+05 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-091 |
Hepatitis B virus DNA (HBV DNA) serum (liquid) reference material |
GBW(E)090991 |
(0.5±0.2)E+02 IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-BW-092 |
GBW(E)090992 |
(1.0±0.2)E+02 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-093 |
GBW(E)090993 |
(2.1±0.4)E+02 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-094 |
GBW(E)090994 |
(5.1±0.8)E+06 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-007 |
GBW(E)090664 |
(2.1±0.8)E+03 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-008 |
GBW(E)090665 |
(2.1±0.7)E+04 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-009 |
GBW(E)090666 |
(2.0±0.6)E+05 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-010 |
GBW(E)090667 |
(2.1±0.6)E+06 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-095 |
Hepatitis C virus RNA (HCV RNA) serum (liquid) reference material |
GBW(E) 090978 |
(0.5±0.2)E+02 IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-BW-096 |
GBW(E) 090979 |
(1.0±0.3)E+02 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-097 |
GBW(E) 090980 |
(2.1±0.4)E+02 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-098 |
GBW(E) 090981 |
(5.0±0.8)E+02 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-011 |
GBW(E)090659 |
( 1.4±0.7) E+03 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-012 |
GBW(E)090660 |
( 1.2±0.5) E+04 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-013 |
GBW(E)090661 |
( 1.4±0.5) E+05 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-014 |
GBW(E)090662 |
( 1.3±0.5) E+06 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-108 |
Human immunodeficiency virus type 1 RNA (HIV-1 RNA) serum (liquid) reference material |
GBW(E)090982 |
(2.1±0.5)E+02 IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-BW-109 |
GBW(E)090983 |
(5.1±0.8)E+02 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-110 |
GBW(E)090984 |
(1.1±0.2)E+03 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-111 |
GBW(E)090985 |
(2.1±0.3)E+03 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-015 |
GBW(E)090663 |
(2.1±0.6)E+04 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-016 |
HPV16 DNA (HPV16 DNA) liquid reference material |
GBW (E)090668 |
(1.1±0.3)E+04 IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-BW-017 |
GBW (E)090669 |
(1.2±0.3)E+05 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-018 |
GBW (E)090670 |
(1.1±0.2)E+06 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-019 |
GBW (E)090671 |
(1.1±0.2)E+07 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-020 |
HPV18 DNA (HPV18 DNA) liquid reference material |
GBW (E)090672 |
(1.1±0.4)E+04 IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-BW-021 |
GBW (E)090673 |
(1.1±0.3)E+05 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-022 |
GBW (E)090674 |
(1.0±0.3)E+06 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-023 |
GBW (E)090675 |
(1.1±0.3)E+07 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-117 |
Novel Coronavirus (SARS-CoV-2) Pseudoviral nucleic acid reference material |
GBW(E)091132 |
(2.0±0.4)E+02 copies/μL |
0.5mL/ tube,5 tubes/kit |
GBDS-BW-118 |
GBW(E)091133 |
(2.0±0.4)E+03 copies/μL |
0.5mL/ tube,5 tubes/kit |
(II) The certified reference material for immunity
Number |
Name |
Approval Number |
Standard Value (IU/ml) |
Dimensions |
GBDS-BW-051 |
Hepatitis B virus surface antigen (HBsAg) serum (fluid) standard material |
GBW(E)090841 |
(0.23±0.09)IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-BW-052 |
GBW(E)090842 |
(0.51±0.09)IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-053 |
GBW(E)090843 |
(5.07±0.64)IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-054 |
GBW(E)090844 |
(10.0±1.30)IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-055 |
GBW(E)090845 |
(25.0±3.30)IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-056 |
Hepatitis B virus surface antibody (HBsAb) serum (liquid) standard material |
GBW(E)090866 |
(5.1±3.6)mIU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-BW-057 |
GBW(E)090867 |
(10.0±3.0)mIU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-058 |
GBW(E)090868 |
(24.9±4.1)mIU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-059 |
GBW(E)090869 |
(49.8±9.8)mIU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-060 |
GBW(E)090870 |
(100±23)mIU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-061 |
Hepatitis B virus e antigen (HBeAg) serum (liquid) standard material |
GBW(E)090871 |
(1.1±0.2)NCU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-BW-062 |
GBW(E)090872 |
(2.1±0.1)NCU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-063 |
GBW(E)090873 |
(4.0±0.4)NCU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-BW-064 |
Hepatitis B virus e antibody (HBeAb) serum (fluid) standard material |
GBW(E)090846 |
(1.0±0.6)NCU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-BW-065 |
GBW(E)090847 |
(2.1±0.4)NCU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-066 |
GBW(E)090848 |
(4.2±0.3)NCU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-067 |
GBW(E)090849 |
(8.0±0.8)NCU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-068 |
Hepatitis B virus core antibody (HBcAb) serum (liquid) standard material |
GBW(E)090862 |
(0.5±0.2)IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-BW-069 |
GBW(E)090863 |
(1.0±0.3)IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-070 |
GBW(E)090864 |
(1.5±0.4)IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-071 |
GBW(E)090865 |
(2.0±0.5)IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-072 |
Human immunodeficiency virus Type 1 antibody (anti-HIV-1) Serum (liquid) reference material |
GBW(E)090858 |
(1.1±0.2)NCU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-BW-073 |
GBW(E)090859 |
(2.0±0.2)NCU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-074 |
GBW(E)090860 |
(4.1±0.3)NCU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-075 |
GBW(E)090861 |
(8.0±0.7)NCU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-076 |
Antibodies to hepatitis C virus (Anti-HCV) serum (liquid) standard Quasi material |
GBW(E)090854 |
(1.1±0.2)NCU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-BW-077 |
GBW(E)090855 |
(2.0±0.2)NCU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-078 |
GBW(E)090856 |
(4.1±0.3)NCU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-079 |
GBW(E)090857 |
(8.0±0.6)NCU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-081 |
Treponema pallidum antibody (anti -TP) serum (liquid) reference material |
GBW(E)090851 |
(6.0±1.4)mIU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-BW-082 |
GBW(E)090852 |
(12.0±2.8)mIU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-BW-083 |
GBW(E)090853 |
(18.1±4.2)mIU/mL |
0.5mL/ tube, 20 tubes/kit |
(III) Hematogenic screening criteria
1. HBsAg/ anti-HCV/anti-HIV-1 / anti-TP mixed serum standard material
(Specification:3.0mL/tube20 tube/kit)
Number |
Name of reference substance |
Approval Number |
Analytical matter |
|||||||
HBsAg IU/mL |
Anti-HIV1 NCU/mL |
Anti-TP mIU/mL |
Anti-HCV NCU/mL |
|||||||
Standard value |
Uncertainty |
Standard values |
Uncertainty |
Standard value |
Uncertainty |
Standard value |
Uncertainty |
|||
GBDS-BW-112 |
HBsAg/resistance HCV/resistance HIV - 1 / resistance TP mixed blood Clear reference material |
GBW(E)090986 |
0.21 |
0.08 |
0.2 |
0.06 |
3.1 |
1.2 |
0.21 |
0.07 |
GBDS-BW-113 |
GBW(E)090987 |
0.2 |
0.08 |
0.47 |
0.12 |
5.9 |
1.8 |
0.52 |
0.14 |
|
GBDS-BW-114 |
GBW(E)090988 |
0.5 |
0.09 |
0.52 |
0.13 |
6.3 |
1.8 |
0.51 |
0.14 |
|
GBDS-BW-115 |
GBW(E)090989 |
0.51 |
0.09 |
1 |
0.2 |
11.9 |
3.3 |
1.2 |
0.13 |
|
GBDS-BW-116 |
GBW(E)090990 |
0.51 |
0.09 |
2.04 |
0.27 |
12.4 |
3.4 |
2.04 |
0.17 |
2. HBV/HCV/HIV-1 nucleic acid mixed serum reference material
Number |
Name of reference substance |
Approval Number |
Analytical matter |
||
HBV DNA (IU/mL) |
HCV RNA (IU/mL) |
HIV1 RNA (IU/mL) |
|||
GBDS-BW-102 |
HBV/HCV/HIV-1 nucleic acid Mixed serum reference material |
GBW(E)090973 |
(3.4±1.1)×10 |
(3.3±1.2) ×10 |
(2.1±0.6) ×10 2 |
GBDS-BW-103 |
GBW(E)090974 |
(5.5±1.4) ×10 |
(5.4±1.5) ×10 |
(2.1±0.5) ×10 2 |
|
GBDS-BW-104 |
GBW(E)090975 |
(5.2±1.3) ×10 |
(2.2±0.5) ×10 2 |
(2.2±0.5) ×10 2 |
|
GBDS-BW-105 |
GBW(E)090976 |
(2.1±0.4) ×10 2 |
(1.2±0.3) ×10 3 |
(1.1±0.2) ×10 3 |
|
GBDS-BW-106 |
GBW(E)090977 |
(5.1±1.6) ×10 2 |
(2.1±1.9) ×103 |
(2.2±1.6) ×10 3 |
(V) Hematogenic screening criteria
1. Nucleic acid indoor quality NAT control products
Number |
Name |
Value of concentration |
Specifications |
|
Concentration |
Range of mean |
|||
GBDS-IQC-001 |
Hepatitis B virus DNA (HBV DNA) serum (liquid) indoor quality NAT control products
|
H (S4) |
1.00E+06~1.00E+07 IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-002 |
M (S3) |
1.00E+05~1.00E+06 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-003 |
L (S2) |
1.00E+04~1.00E+05 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-004 |
Criticality (S1) |
1.00E+03~1.00E+04 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-136 |
L1 |
500 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-137 |
L2 |
200 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-215 |
L3 |
100 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-138 |
L4 |
50 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-140 |
Hepatitis B virus DNA (HBV DNA) genotyping serum quality NAT control product |
Containing common HBV genotypes (B, C, D, Type B+C, etc.) |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-004-6 |
Hepatitis B virus drug resistance gene mutation serum (fluid Body) quality NAT control products |
Containing HBV YVDD, HBV YIDD and other genes |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-004-7 |
Hepatitis B virus DNA serum dried Disturbance material quality NAT control products |
Contains bilirubin, triglyceride, hemoglobin, Albumin, total IgG interfering substance and normal NAT control samples
|
0.5mL/ tube,12 tubes/kit |
GBDS-IQC-005 |
Hepatitis C virus RNA (HCV RNA) serum Indoor quality NAT control products
|
H (S3) |
1.00E+05~1.00E+06 IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-006 |
M (S2) |
1.00E+04~1.00E+05 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-007 |
L (S1) |
1.00E+03~1.00E+04 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-142 |
L1 |
500 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-143 |
L2 |
200 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-216 |
L3 |
100IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-146 |
Hepatitis C virus RNA (HCV RNA) Genotyping serum quality NAT control product |
Contains common HCV RNA genotypes (1a/1b/2a/6a/3a/3b)
|
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-007-5 |
Hepatitis C virus RNA serum interferometer Quality NAT control products |
Contains bilirubin, triglyceride, hemoglobin, Albumin, total IgG interfering substance and normal NAT control samples |
0.5mL/ tube,12tubes/kit |
|
GBDS-IQC-207-4 |
Hepatitis E virus RNA (HEV RNA) Plasma (liquid) indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC--207-3 |
M |
1.00E+04~1.00E+0 5 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC--207-2 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-150 |
Human immunodeficiency virus type 1 RNA (HIV-1 RNA) serum (liquid) indoor quality NAT control products |
H (S3) |
1.00E+04~1.00E+05 IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-151 |
M (S2) |
1.00E+03~1.00E+04 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-152 |
L (S1) |
1.00E+02~1.00E+03IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-195 |
L1 |
1000IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-196 |
L2 |
500IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-197 |
L3 |
100IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-118 |
HBV DNA/HCV RNA Mix (liquid) quality NAT control products
|
H |
1.00E+05~1.00E+06 IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-119 |
M |
1.00E+04~1.00E+05 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-120 |
L |
1.00E+03~1.00E+04 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-223 |
HBV DNA/HCV RNA/HIV1 RNA Mix (liquid) quality NAT control products |
H |
1.00E+05~1.00E+06 IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-224 |
M |
1.00E+04~1.00E+05 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-225 |
L |
1.00E+03~1.00E+04 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-050 |
Epstein-barr virus DNA (EBV DNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-051 |
M |
1.00E+04~1.00E+05 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-052 |
L |
1.00E+03~1.00E+04 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-025 |
Human cytomegalovirus DNA (HCMV DNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-026 |
M |
1.00E+04~1.00E+05 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-027 |
L |
1.00E+03~1.00E+04 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-008 |
Mycoplasma pneumoniae DNA (MP DNA) liquid indoor quality NAT control products |
H |
1.00E+06~1.00E+07 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-009 |
M |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-010 |
L |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-319 |
Chlamydia pneumonia deoxyribonucleic acid (CP DNA) liquid indoor quality NAT control products |
L |
1.00E+03~1.00E+04 copies/mL
|
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-269 |
Humanmetapneumovirus RNA (HMPV RNA) Liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-270 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-271 |
L |
1.00E+03~1.00E+04 copies/mL
|
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-012 |
Gonococcal DNA (NGH DNA) liquid indoor quality NAT control products |
H |
1.00E+06~1.00E+07 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-013 |
M |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-014 |
L |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-022 |
Chlamydia trachomatis DNA (CT DNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-023 |
M |
1.00E+04~1.00E+05copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-024 |
L |
1.00E+03~1.00E+04copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-028 |
Ureaplasma urealyticum deoxyribonucleic acid (UU DNA) liquid indoor quality NAT control products |
H |
1.00E+06~1.00E+07 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-029 |
M |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-030 |
L |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-206 |
Ureaplasmamicrodeoxyribonucleic acid (UPDNA) liquid indoor quality NAT control products |
H |
1.00E+06~1.00E+07 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-207 |
M |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-208 |
L |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-113 |
Chlamydia trachomatis (CT), Ureaplasma urealyticum (UU), Neisseria gonorrhoeae (NGH) DNA liquid Mixed indoor quality NAT control products |
M |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-114 |
L |
1.00E+04~1.00E+05 copies/mL
|
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-127 |
Mycoplasma hominisdeoxyribonucleic acid (MH DNA) liquid indoor quality NAT control products |
H |
1.00E+06~1.00E+07 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-128 |
M |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-129 |
L |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-133 |
Human papillomavirus typing deoxyribonucleic acid Indoor quality NAT control products |
M |
1.00E+05~1.00E+06 copies/mL
|
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-133-2 |
Human papillomavirus deoxyribonucleic acid (HPV DNA) mixed quality NAT control products |
H |
1.00E+06~1.00E+07 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-133-1 |
M |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-133-3 |
L |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-016 |
Human papillomavirus type 16 DNA (HPV16 DNA) liquid indoor quality NAT control products |
H |
1.00E+06~1.00E+07 IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-017 |
M |
1.00E+05~1.00E+06 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-018 |
L |
1.00E+04~1.00E+05 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-019 |
Human papillomavirus type 18 DNA (HPV18 DNA) liquid indoor quality NAT control products |
H |
1.00E+06~1.00E+07 IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-020 |
M |
1.00E+05~1.00E+06 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-021 |
L |
1.00E+04~1.00E+05 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-037 |
Human papillomavirus types 16 and 18 deoxyribose nuclei Acid liquid indoor quality NAT control products |
H |
1.00E+06~1.00E+07 IU/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-038 |
M |
1.00E+05~1.00E+06 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-039 |
L |
1.00E+04~1.00E+05 IU/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-041 |
Human papillomavirus type 6 deoxyribonucleic acid Indoor quality NAT control products |
H |
1.00E+06~1.00E+07 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-042 |
M |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-043 |
L |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-044 |
Human papillomavirus type 11 deoxyribonucleic acid Indoor quality NAT control products |
H |
1.00E+06~1.00E+07 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-045 |
M |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-046 |
L |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-047 |
Human papillomavirus type 6, 11 DNA Liquid indoor quality NAT control products |
H |
1.00E+06~1.00E+07 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-048 |
M |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-049 |
L |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-031 |
Herpes simplex virus type I DNA (HSV I DNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-032 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-033 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-034 |
Herpes simplex virus type II DNA (HSVⅡ DNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-035 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-036 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-321 |
Chickenpox - herpes zoster virus DNA (VZV DNA) liquid indoor quality NAT control products |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-163 |
B group Streptococcus deoxyribonucleic acid (GBS DNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-164 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-165 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-060 |
Mycobacterium tuberculosis deoxyribonucleic acid (TB DNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-059 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-058 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-063 |
Rubella virus RNA (RV RNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-062 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-061 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-390 |
Measles virus RNA indoor quality NAT control products |
S1 |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-260 |
Rubella/measles virus ribonucleic acid mixed liquid chamber Internal quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-261 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-262 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-064 |
Enterovirus 71 RNA (EV71 RNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-065 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-066 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-115 |
Enterovirus universal ribonucleic acid (EV RNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-116 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-117 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-067 |
Coxsackie virus CA16 RNA (CA16 RNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-068 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-069 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-217 |
Coxsackie virus CA6 RNA (CA6 RNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-218 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-219 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-220 |
Coxsackie virus CA10 RNA (CA10 RNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-221 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-222 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-070 |
Group A rotavirus RNA (RWA RNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-071 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-072 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-226 |
Norovirus RNA (NV RNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-227 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-228 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-130 |
Influenza A virus RNA (IVA RNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-131 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-132 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-073 |
Influenza B virus ribonucleic acid (IVB RNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-074 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-075 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-316 |
Type B fluid-sensitive nucleotide nucleoacid (IVB RNA) liquid indoor quality NAT control products (Yamagata Plant) |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-317 |
Type B fluid-sensitive nucleotide nucleoacid (IVB RNA) Liquid indoor quality NAT control products (Victoria Plant) |
L |
1.00E+03~1.00E+04 copies/mL
|
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-173 |
Influenza A/HIN1 viral RNA (HIN1 RNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-174 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-175 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-341 |
Influenza A H3N2 viral RNA (H3N2 RNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-342 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-315 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-176 |
Influenza A H5N1 viral RNA (H5N1 RNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-177 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-178 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-179 |
Influenza A (H7N9) virus RNA (H7N9) RNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-180 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-181 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-182 |
Influenza A H9N2 viral RNA (H9N2 RNA) liquid indoor quality NAT control products
|
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-183 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-184 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-281 |
Influenza A H9N2 viral RNA (H9N2 RNA) liquid indoor quality NAT control products |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-282 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-077 |
Human parainfluenza type 2 virus RNA (PIV2 RNA) liquid indoor quality NAT control products |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-078 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-080 |
Human parainfluenza 3 virus ribonucleic acid (PIV3 RNA) liquid indoor quality NAT control products |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-081 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-083 |
Human parainfluenza 4b virus RNA (PIV4b RNA) liquid indoor quality NAT control products |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-084 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-086 |
Respiratory syncytial virus type A RNA liquid Indoor quality NAT control products |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-087 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-230 |
Respiratory syncytial virus B RNA liquid Indoor quality NAT control products |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-231 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-233 |
Adenovirus DNA (ADV DNA) liquid indoor quality NAT control products |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-234 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-286 |
Adenovirus type 1 deoxyribonucleic acid (ADV1 DNA) liquid indoor quality NAT control products |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-287 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-288 |
Adenovirus type 2 deoxyribonucleic acid (ADV2 DNA) liquid indoor quality NAT control products |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-289 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-264 |
Adenovirus type 3 deoxyribonucleic acid (ADV3 DNA) liquid indoor quality NAT control products |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-265 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-278 |
Adenovirus type 4 deoxyribonucleic acid (ADV4DNA) liquid indoor quality NAT control products |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-279 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-290 |
Adenovirus type 5 deoxyribonucleic acid (ADV5DNA) liquid indoor quality NAT control products |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-291 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-267 |
Adenovirus type 7 deoxyribonucleic acid (ADV7 DNA) liquid indoor quality NAT control products |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-268 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-292 |
Adenovirus type 11 deoxyribonucleic acid (ADV11 DNA) liquid indoor quality NAT control products |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-293 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-294 |
Adenovirus type 14 deoxyribonucleic acid (ADV14 DNA) liquid indoor quality NAT control products |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-295 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-296 |
Adenovirus type 21 deoxyribonucleic acid (ADV21 DNA) liquid indoor quality NAT control products |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-297 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-298 |
Adenovirus type 41 deoxyribonucleic acid (ADV41 DNA) liquid indoor quality NAT control products |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-299 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-300 |
Adenovirus type 48 deoxyribonucleic acid (ADV48 DNA) liquid indoor quality NAT control products |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-301 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-088 |
Dengue virus type I RNA Liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-089 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-090 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-091 |
Dengue virus type II RNA Liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-092 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-093 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-094 |
Dengue virus type III RNA Liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-095 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-096 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-097 |
Dengue virus type IV RNA Liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-098 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-099 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-235 |
Human coronavirus HCoV-OC43 RNA Liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-236 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-237 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-238 |
Human coronavirus HCoV-HKU1 RNA Liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-239 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-240 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-241 |
Human coronavirus HCoV-229E RNA Liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-242 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-243 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-244 |
Human coronavirus HCoV-NL63 RNA Liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-245 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-246 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-247 |
Severe Acute respiratory syndrome coronavirus ribose Nucleic acid (SARS-CoV RNA) liquid chamber Quality NAT control product |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-248 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-249 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-275 |
2019 Novel coronavirus RNA (2019-nCoV RNA) liquid indoor quality NAT control product |
M S2 |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-276 |
L S1 |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-304 |
S0 |
1.00E+02~1.00E+03 copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-305 |
L1 |
500copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-367 |
L2 |
250copies/mL |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-303 |
Negative |
/ |
0.5mL/ tube, 20 tubes/kit |
|
GBDS-IQC-306 |
Novel coronavirus B.1.1.7 mutant nucleoacidIndoor quality NAT control products |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-306-1 |
Nucleoacid of novel coronavirus B.1.351 mutant strain Body NAT control product |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-306-2 |
Nuclear acid constitution of novel coronavirus P.1 mutant strain NAT control products |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-306-3 |
Nucleoacid of novel coronavirus B.1.617 mutant strain Body NAT control product |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-306-4 |
Nucleic acid of Omicron mutant strain of novel coronavirus Liquid quality NAT control products |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-306-5 |
Nucleic acid liquid of novel coronavirus Delta mutant strain Quality NAT control product |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-306-6 |
Mutations in the Omicron BA.2 subtype of the novel coronavirus Nucleic acid liquid quality NAT control products |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-373 |
Monkeypox virus deoxyribonucleic acid liquid indoor quality NAT control product |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube,10 tubes/kit |
GBDS-IQC-374 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube,10 tubes/kit |
|
GBDS-IQC-375 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube,10 tubes/kit |
GBDS-IQC-383 |
Vaccinia virus nucleic acid indoor quality NAT control products |
S1 |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-384 |
Vaccinia virus - Tiantan strain nucleic acid indoor quality NAT control products |
S1 |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-385 |
Camel pox virus nucleic acid indoor quality NAT control products |
S1 |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-386 |
Vaccinia virus nucleic acid indoor quality NAT control products |
S1 |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-387 |
Light smallpox virus nucleic acid indoor quality NAT control products |
S1 |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-388 |
Smallpox virus nucleic acid indoor quality NAT control products |
S1 |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-389 |
Heavy smallpox virus nucleic acid indoor quality NAT control products |
S1 |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube, 20 tubes/kit |
GBDS-IQC-198 |
Middle East Respiratory Syndrome coronavirus (MERS) nuclear Sugar nucleic acid liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-199 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-200 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-255 |
Zika virus RNA liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-256 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-257 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-318 |
Human rhinovirus RNA (HRV RNA) solution Indoor quality NAT control products |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-343 |
Legionella pneumophila DNA liquid chamber Quality NAT control product |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-344 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-320 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-345 |
Staphylococcus aureus deoxyribonucleic acid (SA DNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-346 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-322 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-347 |
Candida albicans DNA liquid chamber Quality NAT control product |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-348 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-323 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-349 |
Candida albicans deoxyribonucleic acid (CG DNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-350 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-324 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-351 |
Pertussis bacteria deoxyribonucleic acid liquid chamber Quality NAT control product |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-352 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-325 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-353 |
Klebsiella pneumoniae deoxyribonucleic acid (KP DNA) liquid indoor quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-354 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-326 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-355 |
Pneumococcal DNA liquid chamber Quality NAT control product |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-356 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-327 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-357 |
The internal deplasticized oxygen NAT control nucleosaccharide nucleic acid liquid chamber of Streptococcus pyogenes |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-358 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-328 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-359 |
Haemophilus influenzae deoxyribonucleic acid liquid indoor quality NAT control |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-360 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-329 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-361 |
Escherichia coli deoxynucleated sugar NAT control product nucleic acid liquid indoor quality |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-362 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-331 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-363 |
Listeria deoxynucleated sugar NAT control product nucleic acid liquid indoor quality |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-364 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-332 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-365 |
Salmonella deoxynucleated sugar NAT control nucleic acid liquid indoor substance |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-366 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-333 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-376 |
Helicobacter pylori DNA liquid chamber Quality NAT control product |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-377 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-378 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-379 |
Pseudomonas aeruginosa DNA liquid chamber Quality NAT control product |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-380 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-381 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-IQC-054 |
α Genetic diagnosis of thalassemia Positive quality NAT control products |
Optional genotypes |
-α 3.7 /αα;-α 4.2 /αα; -SEA/αα;-SEA/-α 3.7; -SEA/-α 4.2;-α 3.7 /-α 4.2, etc. |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-055 |
β Genetic diagnosis of thalassemia Positive quality NAT control products |
Optional genotypes |
β -28 /β N; β CD17 /β N;β CD41-42 /β N;β IVS-2-654 /β N;β CD26 /β N;etc. |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-056 |
α / β Thalassemia gene diagnosis normal quality NAT control products |
Normal person |
Whole blood, αα/αα; β / β |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-100 |
Noninvasive prenatal genetic testing: 21, 13, 18 Quality NAT control for liquid with abnormal number of chromophores |
21, 13, 18 staining trisomy |
21, 13, 18 staining trisomy |
0.7mL/ tube,10 tubes/kit |
GBDS-IQC-101 |
Noninvasive prenatal genetic testing: 21, 13, 18 Number of normal liquid quality NAT control products |
Normal quality NAT control product |
Different chromosomes are optional |
0.7mL/ tube,10 tubes/kit |
GBDS-IQC-254 |
Deafness gene dry blood spot (DBS) quality NAT control products |
Dry blood spot |
12 genes for deafness |
6 Blood spots/kit |
GBDS-IQC-382 |
Metagenomic sequencing quality NAT control products |
S1 |
1.00E+03~1.00E+04 copies/mL |
1ml/tube,5 tube/kit |
GBDS-IQC-103 |
CYP2C19 gene test quality NAT control product |
Liquid |
CYP2C19*2、CYP2C19*3、CYP2C19*17 |
5 tube/kit |
GBDS-IQC-104 |
Folate metabolic capacity (MTHFR) Genotyping whole blood quality NAT control product |
Optional genotypes |
MTHFR Gene |
5 tube/kit |
GBDS-IQC-105 |
CYP3A5 gene test quality NAT control product |
Liquid |
CYP3A5 gene |
5 tube/kit |
GBDS-IQC-106 |
ROS1 gene test quality NAT control product |
Liquid |
ROS1 gene |
5 tube/kit |
GBDS-IQC-107 |
PIK3CAGene mutation quality NAT control products |
Liquid |
PIK3CA gene mutation |
5 tube/kit |
GBDS-IQC-108 |
EGFR Gene mutation quality NAT control products |
Liquid |
EGFR gene mutation |
5 tube/kit |
GBDS-IQC-109 |
KRAS gene mutation quality NAT control products |
Liquid |
KRAS gene mutation |
5 tube/kit |
GBDS-IQC-110 |
BRAF gene mutation quality NAT control products |
Liquid |
BRAF gene mutation |
5 tube/kit |
GBDS-IQC-302 |
ALK gene mutation quality NAT control products |
Liquid |
ALK gene mutation |
5 tube/kit |
GBDS-IQC-201 |
BRCA gene mutation quality NAT control products |
Liquid |
BRCA gene mutation |
5 tube/kit |
GBDS-IQC-202 |
TP53 gene mutation quality NAT control products |
Liquid |
TP53 gene mutation |
5 tube/kit |
GBDS-IQC-111 |
CYP2C9 and VKORC1 gene detection of warfarin Test quality NAT control products |
Liquid |
CYP2C9 and VKORC1 gene |
5 tube/kit |
GBDS-IQC-147 |
Phenylketonuria gene dry blood spot (DBS) quality NAT control product |
Dry blood spot |
4r kinds of PAH genes |
6 Blood spots/kit |
GBDS-IQC-258 |
Human acetaldehyde dehydrogenase 2(ALDH2) gene is abundant State test quality NAT control products |
Liquid |
ALDH2; c.1510G/A, heterozygous mutation |
5 tube/kit |
GBDS-IQC-259 |
Polypeptide of human SLCO1B1 and ApoE genes Check quality NAT control products |
Liquid |
SLCO1B1*1b,SLCO1B1*5、 ApoE2、ApoE4 |
5 tube/kit |
GBDS-IQC-203 |
Human HLA-B27 gene whole blood quality NAT control product |
Whole blood |
HLA-B27 Positive |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-204 |
Leukemia AML1-ETO fusion gene quality NAT control products |
Liquid |
AML1-ETO fusion |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-205 |
Leukemia PML-RARA fusion gene quality NAT control product |
Liquid |
PML-RARA fusion |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-251 |
Leukemia BCR-ABL1 fusion gene quality NAT control product |
Liquid |
BCR-ABL1 fusion |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-285 |
Serum/plasma negative quality NAT control products |
Negative |
Suitable for HBV DNA/HCV RNA/HIV1 RNA/TP DNA and other serum varieties were negative Quality NAT control |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-161 |
Negative quality NAT control products |
Negative |
Applicable to UU DNA/CT DNA/ NGH Negative quality NAT control of DNA and other cultured varieties |
0.5mL/ tube,20 tubes/kit |
GBDS-IQC-151-1 |
HPV negative quality NAT control products |
Negative |
It is suitable for the negative nature of all types of human papilloma NAT control; Human genome containing |
0.5mL/ tube,20 tubes/kit |
2. Immune indoor quality NAT control products
Number |
Name |
Concentration Serial |
Standard Value |
Specification |
GBDS-I-217 |
Novel Coronavirus (SARS-CoV-2) Antigen quality NAT control products |
/ |
Positive |
0.5mL/ tube,20 tubes/kit |
GBDS-I-218 |
Novel Coronavirus (SARS-CoV-2) IgG/IgM antibody quality NAT control product |
/ |
Positive |
0.5mL/ tube,20 tubes/kit |
GBDS-I-001 |
Hepatitis B virus surface antigen (HBsAg) serum (liquid) indoor Quality NAT control product |
S1 |
0.1 IU/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-I-002 |
S2 |
0.2 IU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-003 |
S3 |
0.5 IU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-004 |
S4 |
5.0 IU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-005 |
S5 |
25.0 IU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-006 |
Hepatitis B virus surface antibody (HBsAb) serum (liquid) indoor Quality NAT control product |
S1 |
5 IU/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-I-007 |
S2 |
10 IU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-008 |
S3 |
25 IU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-009 |
S4 |
50 IU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-010 |
S5 |
100 IU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-011 |
Hepatitis B virus e antigen (HBeAg) serum (liquid) indoor Quality NAT control product |
S1 |
1.0 NCU/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-I-012 |
S2 |
2.0 NCU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-013 |
S3 |
4.0 NCU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-014 |
Hepatitis B virus e antibody (HBeAb) serum (liquid) indoor Quality NAT control product |
S1 |
1.0 NCU/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-I-015 |
S2 |
2.0 NCU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-016 |
S3 |
4.0 NCU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-017 |
S4 |
8.0 NCU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-018 |
Hepatitis B virus core antibody (HBcAb) serum (liquid) indoor Quality NAT control product |
S1 |
0.5 NCU/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-I-019 |
S2 |
1.0 NCU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-020 |
S3 |
1.5 NCU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-021 |
S4 |
2.0 NCU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-036 |
Human immunodeficiency virus Type 1 antibody (anti-HIV-1) Serum (liquid) indoor quality NAT control products |
L1 |
0.2 NCU/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-I-035 |
S0 |
0.5 NCU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-022 |
S1 |
1.0 NCU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-023 |
S2 |
2.0 NCU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-024 |
S3 |
4.0 NCU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-025 |
S4 |
8.0 NCU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-219 |
Antibodies to hepatitis C virus (anti-HCV) serum (fluid) chamber Internal quality NAT control products |
L2 |
0.03 NCU/mL |
0.5mL/ tube,20 tubes/kit |
GBDS-I-220 |
L1 |
0.05 NCU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-034 |
S0 |
0.5 NCU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-026 |
S1 |
1.0 NCU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-027 |
S2 |
2.0 NCU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-028 |
S3 |
4.0 NCU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-029 |
S4 |
8.0 NCU/mL |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-030 |
Antibody to Treponema pallidum (anti-TP) Serum (liquid) indoor quality NAT control products |
S1 |
3.0 mIU/ml |
0.5mL/ tube,20 tubes/kit |
GBDS-I-031 |
S2 |
6.0 mIU/ml |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-032 |
S3 |
12 mIU/ml |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-033 |
S4 |
18 mIU/ml |
0.5mL/ tube,20 tubes/kit |
|
GBDS-I-133 |
Prenatal screening indoor quality NAT control products |
S1 |
L |
1.0mL/ bottle, 9 bottles/kit |
GBDS-I-134 |
S2 |
M |
1.0mL/ bottle, 9 bottles/kit |
|
GBDS-I-135 |
S3 |
H |
1.0mL/ bottle, 9 bottles/kit |
|
GBDS-I-136 |
Neonatal screening indoor quality NAT control products |
S1 |
L |
2 blood spots/set, 3 sets/kit |
GBDS-I-137 |
S2 |
M |
(1)G6PD blood spot (2)TSH\Phe\17-OHP |
|
GBDS-I-213 |
S3 |
H |
||
GBDS-I-152 |
A variety of amino acids, carnitine and succinylpropyl Ketone indoor quality NAT control products |
C1 |
L |
There were 5 blood spots in C1 and C2 respectively, 10 Blood spot/set, 1 set/kit |
C2 |
H |
|||
GBDS-I-210 |
Indoor quality NAT control product for immune serum (dry powder) |
S1 |
L |
5.0mL/ bottle, 6 bottles/kit |
GBDS-I-211 |
S2 |
M |
5.0mL/ bottle, 6 bottles/kit |
|
GBDS-I-212 |
S3 |
H |
5.0mL/ bottle, 6 bottles/kit |
V. Performance verification reference (Verification disk)
Number |
Name |
GBDS-CKP-002 |
Hepatitis B virus deoxyribonucleic acid (HBV DNA) serum (liquid) performance evaluation reference |
GBDS-CKP-003 |
Hepatitis C virus ribonucleic acid (HCV RNA) serum (liquid) performance evaluation reference |
GBDS-CKP-032 |
Human immunodeficiency virus type 1 nucleic acid (HIV-1 RNA) serum (liquid) performance evaluation reference |
GBDS-CKP-012 |
Serum (liquid) performance verification reference for blood-derived screening of hepatitis B virus nucleic acid (HBV DNA) |
GBDS-CKP-036 |
Blood-derived screening hepatitis C virus nucleic acid (HCV RNA) serum (liquid) performance verification reference |
GBDS-CKP-037 |
Reference for serum (liquid) performance verification for blood-derived screening of human immunodeficiency virus type I nucleic acid (HIV-1 RNA) |
GBDS-CKP-030 |
Hepatitis B virus nucleic acid (HBV DNA)/Hepatitis C virus nucleic acid (HCV RNA)/Human immunodeficiency 1 Type II virus nucleic acid (HIV-1 RNA) system performance verification disk |
GBDS-CKP-031 |
Hepatitis B virus nucleic acid (HBV DNA)/Hepatitis C virus nucleic acid (HCV RNA)/Human immunodeficiency 1 Type II virus nucleic acid (HIV-1 RNA) analysis sensitivity verification disk |
GBDS-CKP-007 |
Chlamydia trachomatis deoxyribonucleic acid (CT DNA) liquid performance evaluation reference |
GBDS-CKP-001 |
Ureaplasma Urealyticum deoxyribonucleic acid (UU DNA) liquid performance evaluation reference |
GBDS-CKP-009 |
Neisseria gonorrhoeae deoxyribonucleic acid (NGH DNA) liquid performance evaluation reference |
GBDS-CKP-010 |
Human cytomegalovirus deoxyribonucleic acid (HCMV DNA) liquid performance evaluation reference |
GBDS-CKP-011 |
Epstein-barr virus deoxyribonucleic acid (EBV DNA) liquid performance evaluation reference |
GBDS-CKP-020 |
Mycobacterium tuberculosis deoxyribonucleic acid (TB DNA) liquid performance evaluation reference |
GBDS-CKP-008 |
Mycoplasma pneumoniae deoxyribonucleic acid (MP DNA) liquid performance evaluation reference |
GBDS-CKP-004 |
Human papillomavirus typing deoxyribonucleic acid (HPV DNA) liquid performance evaluation reference |
GBDS-CKP-005 |
EGFR mutant reference |
GBDS-CKP-006 |
KRAS mutant reference |
GBDS-CKP-015 |
Influenza virus nucleic acid detection performance verification reference |
GBDS-CKP-005 |
EGFR mutant reference |
GBDS-CKP-006 |
KRAS mutant reference |
GBDS-CKP-015 |
Influenza virus nucleic acid detection performance verification reference |
GBDS-CKP-016 |
Hand-foot-mouth virus nucleic acid detection performance verification reference |
GBDS-CKP-018 |
Reference for validation of serum (fluid) performance in the genetic diagnosis of α/β thalassemia |
GBDS-CKP-019 |
Group B Streptococcus deoxyribonucleic acid liquid performance evaluation reference |
GBDS-CKP-034 |
Novel coronavirus (SARS-CoV-2) nucleic acid detection performance verification reference |
GBDS-CKP-035 |
Novel Coronavirus (SARS-CoV-2) nucleic acid Detection performance Verification reference (4 tubes/set) |
GBDS-CKP-038 |
Reference for performance verification of multiple nucleic acid detection of respiratory pathogens |
GBDS-CKP-039 |
Monkeypox virus nucleic acid detection performance verification reference |
GBDS-CKP-201 |
Hepatitis B virus surface antigen (HBsAg) detection of serum (liquid) performance verification reference |
GBDS-CKP-202 |
Hepatitis B virus surface antibody (HBsAb) detection of serum (liquid) performance verification reference |
GBDS-CKP-203 |
Hepatitis B virus e antigen (HBeAg) detection of serum (liquid) performance verification reference |
GBDS-CKP-204 |
Hepatitis B virus e antibody (HBeAb) detection of serum (liquid) performance verification reference |
GBDS-CKP-205 |
Hepatitis B virus core antibody (HBcAb) test serum (liquid) performance verification reference |
GBDS-CKP-206 |
Hepatitis C virus antibody (anti-HCV) test serum (liquid) performance verification reference |
GBDS-CKP-207 |
Human immunodeficiency virus type 1 antibody (anti-HIV-1) test serum (liquid) performance verification reference |
GBDS-CKP-208 |
Treponema pallidum (TP) antibody detection serum (liquid) performance verification reference |
GBDS-CKP-209 |
Blood source screening HBsAg/ anti-HCV/anti-HIV-1 / anti-TP test serum (liquid) performance verification reference |
GBDS-CKP-210 |
Novel coronavirus antigen detection performance verification reference |
VI. Laboratory quality assessment of clinical laboratory center
Number |
Name |
Specification |
GBDS-EQA-001 |
Hepatitis B virus deoxyribonucleic acid (HBV DNA) serum (liquid) interventricular quality assessment |
0.5mL/ tube; 5 tubes/set |
GBDS-EQA-002 |
Hepatitis C virus ribonucleic acid (HCV RNA) serum interventricular quality assessment |
0.5mL/ tube; 5 tubes/set |
GBDS-EQA-046 |
Human immunodeficiency virus type 1 RNA (HIV-1 RNA) serum (liquid) interstitial Evaluation of content |
0.5mL/ tube; 5 tubes/set |
GBDS-EQA-003 |
Liquid interventricular quality assessment of Chlamydia trachomatis deoxyribonucleic acid (CT DNA) |
0.5mL/ tube; 5 tubes/set |
GBDS-EQA-004 |
Liquid interventricular quality assessment of Ureaplasma Urealyticum deoxyribonucleic acid (UU DNA) |
0.5mL/ tube; 5 tubes/set |
GBDS-EQA-005 |
Evaluation of NGH DNA in liquid intraventricular quality |
0.5mL/ tube; 5 tubes/set |
GBDS-EQA-006 |
Human papillomavirus (HPV) typing deoxyribonucleic acid liquid intraventricular quality assessment |
0.5mL/ tube; 5 tubes/set |
GBDS-EQA-009 |
Human papillomavirus type 16, 18 deoxyribonucleic acid liquid intraventricular quality assessment |
0.5mL/ tube; 5 tubes/set |
GBDS-EQA-010 |
Human papillomavirus type 6, 11 deoxyribonucleic acid liquid intraventricular quality assessment |
0.5mL/ tube; 5 tubes/set |
GBDS-EQA-011 |
Liquid interventricular quality assessment of herpes simplex virus type Ⅱ deoxyribonucleic acid (HSVⅡ DNA) |
0.5mL/ tube; 5 tubes/set |
GBDS-EQA-012 |
Evaluation of MP DNA liquid interventricular quality of Mycoplasma pneumoniae |
0.5mL/ tube; 5 tubes/set |
GBDS-EQA-015 |
Evaluation of human cytomegalovirus deoxyribonucleic acid (HCMV DNA) liquid intraventricular quality |
0.5mL/ tube; 5 tubes/set |
GBDS-EQA-016 |
Liquid interventricular quality assessment of Mycobacterium tuberculosis deoxyribonucleic acid (TB DNA) |
0.5mL/ tube; 5 tubes/set |
GBDS-EQA-017 |
Mycobacterium tuberculosis deoxyribonucleic acid (TB DNA) liquid interventricular quality assessment of Epstein-Barr virus deoxyribonucleic acid (EBV DNA) liquid interventricular quality assessment |
0.5mL/ tube; 5 tubes/set |
GBDS-EQA-019 |
Noninvasive prenatal genetic testing: fluid interventricular quality assessment for chromosome number abnormalities in 21, 13, and 18 |
1.0mL/ tube; 5 tubes/set |
GBDS-EQA-021 |
Liquid intraventricular quality assessment of α and β thalassaemia genotypes |
0.5mL/ tube; 5 tubes/set |
GBDS-EQA-022 |
Blood derived screening of HBV/HCV/HIV1 virus nucleic acid liquid intraventricular quality assessment |
3.0mL/ tube; 5 tubes/set |
GBDS-EQA-039 |
Interventricular quality evaluation of HBV deoxyribonucleic acid and HCV ribonucleic acid mixed serum |
3.0mL/ tube; 5 tubes/set |
GBDS-EQA-040 |
Interventricular quality evaluation of HBV deoxyribonucleic acid and HCV ribonucleic acid mixed serum |
1.0mL/ tube; 5 tubes/set |
GBDS-EQA-041 |
Interventricular quality assessment for dry blood spots (DBS) of Deafness gene (9 mutation points/blood spots) |
5 Blood spots/set |
GBDS-EQA-042 |
Interventricular quality assessment of phenylketonuria gene dry blood spot (DBS) |
5 Blood spots/set |
GBDS-EQA-043 |
Mixed NG/CT/UU qualitative nucleic acid interventricular quality assessment |
0.5mL/ tube; 5 tubes/set |
GBDS-EQA-050 |
An interventricular quality assessment of hand, foot and mouth EV71 and CA16 virus nucleic acid |
0.5mL/ tube; 5 tubes/set |
GBDS-EQA-051 |
Interventricular quality evaluation of influenza virus nucleic acid |
0.5mL/ tube; 5 tubes/set |
GBDS-EQA-052 |
Evaluation of nucleic acid of group B streptococcus |
0.5mL/ tube; 5 tubes/set |
GBDS-EQA-053 |
Interventricular quality assessment of EGFR gene mutation |
5 tubes/set |
GBDS-EQA-054 |
Interventricular quality assessment of KRAS gene mutation |
5 tubes/set |
GBDS-EQA-055 |
Evaluation of BRAF gene mutation interventricular quality |
5 tubes/set |
GBDS-EQA-056 |
Interventricular quality assessment of ROS1 gene mutation |
5 tubes/set |
GBDS-EQA-057 |
Interventricular quality assessment of ALK gene mutation |
5 tubes/set |
GBDS-EQA-058 |
Interventricular quality assessment of BRCA1/BRCA2 gene mutations |
5 tubes/set |
GBDS-EQA-059 |
Interventricular quality assessment of PIK3CA gene mutation |
5 tubes/set |
GBDS-EQA-060 |
Interventricular quality assessment of TP53 gene mutation |
5 tubes/set |
GBDS-EQA-061 |
Interventricular quality assessment of NRAS gene mutation |
5 tubes/set |
GBDS-EQA-062 |
Interventricular quality assessment of HRAS gene mutation |
5 tubes/set |
GBDS-EQA-063 |
Interventricular quality evaluation of KIT gene mutation |
5 tubes/set |
GBDS-EQA-064 |
Interventricular quality assessment of novel coronavirus RNA |
0.5mL/tube; 5 tubes/set |
GBDS-EQA-065 |
Interlaboratory quality assessment for multiple nucleic acid detection of respiratory pathogens |
0.5mL/tube; 5 tubes/set |
GBDS-EQA-023 |
Interlaboratory quality assessment for Serological markers of Infectious Diseases (HBV 5 + anti-HCV + anti-TP) |
2.0mL/tube; 5 tubes/set |
GBDS-EQA-024 |
Interventricular qualitative evaluation of tumor markers |
1.0mL/tube; 5 tubes/set |
GBDS-EQA-025 |
Immunoendocrine interventricular quality assessment |
2.0mL/tube; 5 tubes/set |
GBDS-EQA-026 |
Interventricular quality evaluation for Neonatal Genetic Metabolic Disease Screening 1 (blood spots) |
0.5mL/tube; 5 tubes/set |
GBDS-EQA-027 |
Interventricular quality evaluation for Neonatal Genetic Metabolic Disease Screening 2 (blood spots) |
0.5mL/tube; 5 tubes/set |
GBDS-EQA-029 |
Interventricular quality Assessment for Screening Neonatal genetic metabolic diseases by tandem mass spectrometry (blood spots) |
0.5mL/tube; 5 tubes/set |
GBDS-EQA-030 |
Interlaboratory quality assessment of maternal serum for prenatal screening in early pregnancy |
0.5mL/tube; 5 tubes/set |
GBDS-EQA-031 |
Interlaboratory quality assessment of maternal serum for prenatal screening during the second trimester |
0.5mL/tube; 5 tubes/set |
GBDS-EQA-032 |
HBsAg/ anti-HCV/anti-HIV-1 / anti-TP interventricular quality assessment |
2.0mL/tube; 5 tubes/set |
GBDS-EQA-036 |
Hepatitis B virus surface antigen (HBsAg) serum interventricular quality assessment |
0.5mL/tube; 5 tubes/set |
GBDS-EQA-037 |
Hepatitis C virus antibody (anti -HCV) serum interventricular quality assessment |
0.5mL/tube; 5 tubes/set |
GBDS-EQA-038 |
Human immunodeficiency virus (HIV) type 1 antibody serum interventricular quality assessment |
0.5mL/tube; 5 tubes/set |
GBDS-EQA-049 |
Interventricular quality assessment of serum antibodies to Treponema pallidum (TP) |
0.5mL/tube; 5 tubes/set |
Ⅶ. In vitro diagnostic reagent
Number |
Name |
Test principle/application |
Specification |
GBDS-BCY-001 |
Sample preservation solution (YSXB No. 20160299)
|
Inactivation principle: Guanidine salt can denature proteins, dissolve proteins and make proteins the cytoplasmic secondary structure disappears, resulting in cell structure degradation and rapid separation of nucleoprotein from nucleic acid away. Protein denaturation can be used to inactivate freshly collected clinical samples use, greatly reduce the sampling process of medical personnel, sample transport process, inspection process the risk of biological transmission in The clinical sample was completely immersed in the preservation solution for 5 minutes, to inactivate viruses/other microorganisms in the sample. Stability principle: Guanidine salt not only has the function of precipitation protein, but also has inhibit the action of nuclease, so as to ensure that the released nucleic acid is not degraded. into split nucleic acid protectors can be very good for nucleic acids, especially single-stranded RNA to the protective effect that allows the RNA to be preserved. For those who cannot be detected in time bed samples or samples that need to be transported long distances play a very good protective role in preventing Stop the degradation of viral nucleic acid in the sample. |
1 mL/tube, 100 tubes/kit |
GBDS-BCY-002 |
2 mL/tube, 100 tubes/kit |
||
GBDS-BCY-005 |
3 mL/tube, 100 tubes/kit |
||
GBDS-BCY-004 |
6 mL/tube, 50 tubes/kit |
||
GBDS-BCY-003 |
6 mL tube, 128tubes/kit |
||
GBDS-BCY-006 |
40 mL/tube/ bag |
||
GBDS-BCY-012 |
40 mL/tube, 5 tube/bag |
||
GBDS-BCY-013 |
200 mL/bottle/bag |
||
GBDS-BCY-007 |
500 mL/bottle/bag |
||
GBDS-BCY-011 |
Sample preservation solution (YSXB No. 20160298)
|
Stability principle: The main component has the effect of inhibiting nuclease, thus protecting the released nucleic acid is not degraded. Clinical markers that cannot be detected in time. This or the need for long-distance transportation of specimens to play a good protective role, can prevent labeling degradation of viral nucleic acids in the virus.
|
1 mL/tube, 100 tubes/kit |
GBDS-BCY-014 |
2 mL/tube, 100 tubes/kit |
||
GBDS-BCY-015 |
3 mL/tube, 100 tubes/kit |
||
GBDS-BCY-016 |
6 mL/tube, 50 tubes/kit |
||
GBDS-BCY-017 |
6 mL/tube, 128 tubes/kit |
||
GBDS-BCY-018 |
400 mL/tube/ bag |
||
GBDS-BCY-019 |
40 mL/tube, 5 tubes/bag |
||
GBDS-BCY-020 |
200 mL/bottle/ bag |
||
GBDS-BCY-021 |
500 mL/bottle bag |
||
GBDS-XSY-001 |
Sample diluent (YSXB No. 20160305)
|
Its principle is to inhibit RNase activity, which can effectively protect RNA from degradation, so as to have better dilution efficiency. It can be used to dilute samples such as serum, plasma or pathogen culture solution. |
1 mL/tube, 100 tubes/kit |
GBDS-XSY-002 |
2 mL/tube, 100 tubes/kit |
||
GBDS-XSY-003 |
3 mL/tube, 100 tubes/kit |
||
GBDS-XSY-004 |
6 mL/tube, 50 tubes/kit |
||
GBDS-XSY-005 |
6 mL/tube, 128 tubes/kit |
||
GBDS-XSY-006 |
400 mL/tube/ bag |
||
GBDS-XSY-007 |
40 mL/tube, 5 tubes/bag |
||
GBDS-XSY-008 |
200 mL/bottle/bag |
||
GBDS-XSY-009 |
500 mL/bottle/bag |
GBDS-XSY-010 |
Sample diluent (YSXB No. 20160303)
|
Its principle is to inhibit DNase activity, which can effectively protect DNA from degradation, so as to have better dilution efficiency. It can be used for dilution of DNA serum, plasma or pathogen culture solution. |
1 mL/tube, 100 tubes/kit |
GBDS-XSY-011 |
2 mL/tube, 100 tubes/kit |
||
GBDS-XSY-012 |
3 mL/tube, 100 tubes/kit |
||
GBDS-XSY-013 |
6 mL/tube, 50 tubes/kit |
||
GBDS-XSY-014 |
6 mL/tube, 128 tubes/kit |
||
GBDS-XSY-015 |
400 mL/tube/ bag |
||
GBDS-XSY-016 |
40 mL/tube, 5 tubes/bag |
||
GBDS-XSY-017 |
200 mL/bottle/bag |
||
GBDS-XSY-018 |
500 mL/bottle/bag |
||
GBDS-XSY-008 |
Disposable sampler (YSXB No. 20200106)
|
The equilibrium salt solution in the sample preservation solution provides a stable living environment, facilitates the preservation of viral infections, and helps the virus particles to be stored in colloidal dispersions, reducing or inhibiting the reaction of damaging nucleic acids. Antibiotics have broad-spectrum antibacterial effects. |
20 tests/kit |
GBDS-XSY-009 |
50 tests/kit |
||
GBDS-XSY-010 |
100 tests/kit |
||
GBDS-CYQ-001 |
Disposable sampler (YSXB No. 20210276) |
Inactivation principle: Guanidine thiocyanate in sample preservation solution can denature protein, dissolve protein and make protein secondary structure disappear, resulting in cell structure degradation and rapid separation of nucleoprotein from nucleic acid. It can inactivate the newly collected clinical samples by protein denaturation, greatly reducing the risk of biological infection in the sampling process of medical staff, sample transport process and inspection process. Inactivation time: The virus/other microorganisms in the samples can be inactivated by completely soaking the clinical samples in the preservation solution for 5 minutes. Stability principle: Guanidine salt not only has the function of precipitation protein, but also has the function of inhibiting nuclease, so as to ensure that the released nucleic acid is not degraded. It can protect the clinical samples that cannot be tested in time or the samples that need to be transported long distance, and prevent the degradation of viral nucleic acid in the samples. |
20 tests/kit |
GBDS-CYQ-002 |
50 tests/kit |
||
GBDS-CYQ-003 |
100 tests/kit |
GBDS-SFJ-009 |
Sample release agent (YSXB No. 20200597 )
|
Through the denaturation of proteins of cells or viruses, the dissolution of proteins and the disappearance of protein secondary structure leads to the degradation of cell or virus structure and the rapid separation of nuclear proteins from nucleic acids. The newly collected clinical samples of pathogens can be inactivated by protein denaturing, and the nucleic acid can be quickly released to protect the nucleic acid from degradation. The clinical samples of pathogens stored in the sample release agent can be directly used for PCR, real-time fluorescence PCR and other tests without heating or other nucleic acid extraction operations. |
0.5 mL/tube, 100 tubes/kit |
GBDS-SFJ-001 |
1 mL/tube, 100 tubes/kit |
||
GBDS-SFJ-002 |
2 mL/tube, 100 tubes/kit |
||
GBDS-SFJ-003 |
3 mL/tube, 100 tubes/kit |
||
GBDS-SFJ-004 |
5 mL/tube, 50 tubes/kit |
||
GBDS-SFJ-005 |
5 mL/tube, 128 tubes/kit |
||
GBDS-SFJ-006 |
6 mL/tube, 50 tubes/kit |
||
GBDS-SFJ-007 |
5 mL/tube, 128 tubes/kit |
||
GBDS-SFJ-008 |
40 mL/tube, 5 tubes/bag |
||
GBDS-TQY-001 |
Nucleic acid extraction or purification reagent (YSXB No. 20201476 ) |
The cells and viruses in the sample are lysed by lysate, and nucleic acid, protein and other impurities are released. The nucleic acid is selectively adsorbed on the surface of the magnetic bead, and then the residual protein, inorganic salt ions and organic impurities are removed by the action of the washing solution. Finally, pure nucleic acid was obtained by elution solution. It can be used for the extraction, enrichment and purification of nucleic acid. The treated products were used for clinical in vitro detection. |
Pre-packaged: 32 reaction/kit |
GBDS-TQY-002 |
Pre-packaged: 96 reaction/kit |
||
GBDS-TQY-003 |
Large package: 100 reaction/box |
||
GBDS-TQY-004 |
Nucleic acid extraction or purification reagent (YSXB No. 20211008) |
The cells and viruses in the sample are lysed by lysate, and nucleic acid, protein and other impurities are released. The nucleic acid is selectively adsorbed on the surface of the magnetic bead, and then the residual protein, inorganic salt ions and organic impurities are removed by the action of the washing solution. Finally, pure nucleic acid was obtained by elution solution. It can be used for nucleic acid extraction, enrichment and purification of FFPE samples. |
16 reaction/kit |
Ⅷ. Animal disease quality NAT control objects
1. Standard material for animal epidemics
Number |
Name |
Certificate Number |
Standard (copies/µL) |
Specification |
GBDS-BW-084 |
European strain of porcine Reproductive and Respiratory syndrome virus (PRRSV LV) nucleic acid reference material |
GBW(E)090928 |
(1.83±0.22)E+04
|
0.5 mL/tube, 2 tubes/kit |
GBDS-BW-085 |
American variant of porcine Reproductive and Respiratory syndrome virus (PRRSV JXA1) nucleic acid reference material
|
GBW(E)090929
|
(1.13±0.18)E+04
|
0.5 mL/tube, 2 tubes/kit |
GBDS-BW-086 |
American classical strain of porcine Reproductive and respiratory syndrome virus (PRRSV VR2332) nucleic acid reference material
|
GBW(E)090930
|
(2.06±0.31)E+04
|
0.5 mL/tube, 2 tubes/kit |
GBDS-BW-087 |
African swine Fever virus B646L gene plasmid standard mass |
GBW(E)091034
|
(5.8±0.9)E+03 |
0.5 mL/tube, 2 tubes/kit |
2. Animal disease quality NAT control products
Number |
Name |
Concentration value |
Specification |
Method of setting value |
|
Concentration |
Concentration range |
||||
GBDS-IQC-1001 |
Porcine Reproductive and Respiratory syndrome virus European strain (PRRSV LV) quality NAT control product |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1002 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1003 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1004 |
Porcine Reproductive and Respiratory syndrome virus American Variant (PRRSV JXA1) quality NAT control product |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1005 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1006 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1067 |
Porcine Reproductive and Respiratory syndrome virus American Classical Bead (PRRSV VR2332) Quality NAT control product |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1068 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1069 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1007 |
Foot and mouth disease virus (FMDV) type A /O /Asia-1 nucleic acid quality NAT control product |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1008 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1009 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1010 |
Streptococcus SUIS DNA (SUIS DNA) Quality NAT control product
|
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR Digital PCR method |
GBDS-IQC-1011 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1012 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1013 |
Mycoplasma porcine nucleic acid quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Combined with Quantitative Real-time PCR Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1014 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1015 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1016 |
African swine Fever virus B646L gene plasmid quality NAT control product |
H |
1.00E+06~1.00E+07copies/mL |
0.2mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR Digital PCR method |
GBDS-IQC-1017 |
M |
1.00E+05~1.00E+06 copies/mL |
0.2mL/tube |
||
GBDS-IQC-1018 |
L |
1.00E+04~1.00E+05 copies/mL |
0.2mL/tube |
||
GBDS-IQC-1019 |
Porcine Parvovirus DNA (PPV DNA) Quality NAT control product |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Combined with Quantitative Real-time PCR Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1020 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1021 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1082 |
Porcine circovirus 1 type nucleic acid (PCV1 DNA) quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR Digital PCR method |
GBDS-IQC-1083 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1084 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1022 |
Porcine circovirus 2 type nucleic acid (PCV 2 DNA) quality NAT control product |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Combined with Quantitative Real-time PCR Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1023 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1024 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1025 |
PRV DNA (PRV DNA) quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1026 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1027 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1028 |
Nucleic acid of Erysipelas porcine (SER DNA) Quality NAT control product |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR
|
GBDS-IQC-1029 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1030 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1031 |
Pasteurella multocida nucleic acid quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1032 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1033 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1034 |
Swine transmissible gastroenteritis,porcine epidemic diarrhea virus nucleic acid quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1035 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1036 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1037 |
Pig Japanese encephalitis virus nucleic acid quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1038 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1039 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
Number |
Name |
Concentration value |
Specification |
Method of setting value |
|
Concentration |
Concentration range |
||||
GBDS-IQC-1046 |
Newcastle Disease virus nucleic acid (NDV RNA) Quality NAT control product |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1047 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1048 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1049 |
Chicken infectious Bursal virus (IBD RNA) nucleic acid quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1050 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1051 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1052 |
Chicken Marek's disease Turkey herpesvirus (MDV DNA) nucleic acid quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1053 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1054 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1055 |
Rabies virus nucleic acid quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1056 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1057 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1058 |
Sheep Clostridium (rapid disease, strike strike, enterotoxemia) nucleic acid quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1059 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1060 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1061 |
Goat pox virus nucleic acid quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1062 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1063 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
GBDS-IQC-1064 |
Goat infectious pleurisy nucleic acid quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1065 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1066 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1076 |
General influenza virus quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1077 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1078 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1079 |
Porcine Pseudorabies virus (PRV) plasmid NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1080 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1081 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1085 |
African swine Fever virus (ASFV) nucleic acid NAT control products |
H |
1.00E+06~1.00E+07 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1086 |
M |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1087 |
L |
1.00E+04~1.00E+07 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1088 |
Swine fever virus nucleic acid (CSFV RNA) Quality NAT control product |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1089 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1090 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1040 |
Avian Influenza virus H5 subtype (AIV-H5) Nucleic acid quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1041 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1042 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1073 |
Avian Influenza virus H7 subtype (AIV-H7) Nucleic acid quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1074 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1075 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1043 |
Avian Influenza virus H9 subtype (AIV-H9) Nucleic acid quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1044 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1045 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1091 |
Avian influenza virus H5/ H7/ H9 universal nucleic acid quality NAT control products |
H |
1.00E+05~1.00E+06 copies/mL |
0.5mL/tube |
Digital PCR method Combined with Quantitative Real-time PCR |
GBDS-IQC-1092 |
M |
1.00E+04~1.00E+05 copies/mL |
0.5mL/tube |
||
GBDS-IQC-1093 |
L |
1.00E+03~1.00E+04 copies/mL |
0.5mL/tube |